11th Circ. Won't Rehear Catalyst's Win In 'Orphan Drug' Case
The Eleventh Circuit declined on Friday a bid to rehear its finding that the U.S. Food and Drug Administration unlawfully infringed on an exclusivity period it awarded Catalyst Pharmaceuticals Inc. for...To view the full article, register now.
Already a subscriber? Click here to view full article